Singapore markets closed

Xeris Pharmaceuticals, Inc. (XERS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.2500-0.1400 (-4.13%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.3900
Open3.3900
Bid3.2400 x 2900
Ask3.2800 x 2900
Day's range3.2450 - 3.4800
52-week range2.4500 - 7.9400
Volume2,156,893
Avg. volume2,548,704
Market cap215.587M
Beta (5Y monthly)1.82
PE ratio (TTM)N/A
EPS (TTM)-2.1370
Earnings date09 Mar 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.25
  • Business Wire

    Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021

    Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that the Company will release its first quarter 2021 financial results before the open of the U.S. financial markets on Thursday, May 13, 2021. Management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company’s financial and operational results.

  • Business Wire

    Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank

    Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has entered into an amendment to its existing loan and security agreement with Oxford Finance LLC (Oxford) and Silicon Valley Bank (SVB). The amendment allows for extensions of interest-only payments for up to 12 months, subject to certain conditions, to January 2023. The extensions allow the Company to delay principal payments of up to $17.4 million, which would have been due during the periods between January 1, 2022 and December 1, 2022, to periods beginning January 1, 2023. The final maturity date of the debt facility is June 1, 2024.

  • Xeris Pharmaceuticals (XERS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
    Zacks

    Xeris Pharmaceuticals (XERS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Xeris Pharmaceuticals (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.